Study of 5-azacitidine in Combination With Vorinostat in Patients With Relapsed or Refractory Diffuse Large b Cell Lymphoma (DLBCL)

Inclusion Criteria

• •Patients must have histologically confirmed diffuse large B cell lymphoma, relapsed after or resistant to prior systemic therapy.
• •Subjects must have measurable disease on cross sectional imaging that is at least 1.5 cm in diameter.
• •Patients should have relapsed following or be deemed ineligible for autologous stem cell transplantation. There is no limit to number of prior therapies.
• •Age \> = 18 years.
• •ECOG performance status \< = 2.
• •Patients must have normal organ and marrow function as defined below:
• •* ANC \> = 1,000/uL
• •* platelets \> = 75,000//uL
• •* total bilirubin \< = 2 X upper limit of normal
• •* AST(SGOT)/ALT(SGPT) \< = 2.5 X upper limit of normal
• •* Serum creatinine \< = 1.5 X upper limit of normal (ULN)
• •Women of childbearing potential must have a negative serum pregnancy test prior to treatment
• •The effects of these investigational agents on the developing human fetus at the recommended therapeutic doses are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. A woman who becomes pregnant while participating in the study must withdraw from the study immediately.
• •Ability to understand and the willingness to sign a written informed consent document.